// App-Quantinova.ai

1000 : Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.

Researchers

Presenter

  • Massimo Cristofanilli

Principal Investigators

  • Hope S. Rugo

  • Seock-Ah Im

  • Dennis J. Slamon

  • Nadia Harbeck

  • Igor Bondarenko

  • Norikazu Masuda

  • Marco Colleoni

  • Angela DeMichele

  • Sherene Loi

  • Hiroji Iwata

  • Ben O'Leary

  • Eustratios Bananis

  • Yuan Liu

  • Xin Huang

  • Sindy Kim

  • Mariajose Lechuga

  • Nicholas C. Turner

Medical Centers

  • Robert H. Lurie Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago, IL

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)

  • David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

  • Brustzentrum der Universitat Munchen (LMU), Munich, Germany

  • Dnipropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital, Dnipropetrovsk, Ukraine

  • National Hospital Organization Toneyama National Hospital, Toyonaka, Japan

  • European Institute of Oncology, Milan, Italy

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia

  • Aichi Cancer Center Hospital, Nagoya, Japan

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Pfizer Inc, New York, NY

  • Pfizer Inc, San Diego, CA

Locations

  • United States

  • Germany

  • Ukraine

  • Japan

  • Italy

  • Australia

  • United Kingdom

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

  • Circulating DNA

Drug/Treatment

  • Fulvestrant

  • Palbociclib

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT01942135

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved